Matches in SemOpenAlex for { <https://semopenalex.org/work/W4288926425> ?p ?o ?g. }
- W4288926425 endingPage "102443" @default.
- W4288926425 startingPage "102443" @default.
- W4288926425 abstract "Diffuse large B-cell lymphoma (DLBCL) is nowadays a curable disease with the frontline treatment R-CHOP, but 30-40% of patients are still unresponsive or relapse thereafter. In the recent era several upcoming new options are improving the therapeutic landscape for relapsed/refractory (R/R) DLBCL setting, first of all anti-CD19 chimeric antigen receptor T-cells (CAR-T) that already represent a standard of care as third-line therapy and are rapidly moving as second-line treatment for those who are refractory or early relapse after R-CHOP. Among these new therapies, the combinations polatuzumab plus rituximab and bendamustine, tafasitamab plus lenalidomide for transplant ineligible patients, and CD3xCD20 bispecific antibodies are the most relevant, but several other agents and strategies are on the way. On the other hand, in the last 20 years, several efforts have been spent in the attempt to ameliorate the outcome over R-CHOP for the frontline treatment of DLBCL shortening the interval between the cycles or intensifying treatment or adding novel drugs to R-CHOP without success, so far. Recent studies combining the anti-CD79b antibody-drug conjugate polatuzumab vedotin plus R-CHP and the anti-BCL2 agent venetoclax plus R-CHOP showed promising results. Preliminary data of new upcoming strategies characterized by a tailored therapy based on different molecular subtypes of DLBCL are encouraging, showing a benefit over the standard R-CHOP. In this manuscript, the literature data on the landscape of new therapies available and upcoming for both frontline and R/R settings of DLBCL will be critically reviewed." @default.
- W4288926425 created "2022-07-31" @default.
- W4288926425 creator A5000403848 @default.
- W4288926425 creator A5044141236 @default.
- W4288926425 creator A5055251201 @default.
- W4288926425 creator A5074890337 @default.
- W4288926425 creator A5081994993 @default.
- W4288926425 date "2022-11-01" @default.
- W4288926425 modified "2023-10-16" @default.
- W4288926425 title "Treatment strategies for patients with diffuse large B-cell lymphoma" @default.
- W4288926425 cites W1020989877 @default.
- W4288926425 cites W1997353354 @default.
- W4288926425 cites W2021130630 @default.
- W4288926425 cites W2059524199 @default.
- W4288926425 cites W2100090512 @default.
- W4288926425 cites W2109440389 @default.
- W4288926425 cites W2111716055 @default.
- W4288926425 cites W2111827890 @default.
- W4288926425 cites W2126779872 @default.
- W4288926425 cites W2127018518 @default.
- W4288926425 cites W2133345449 @default.
- W4288926425 cites W2135860817 @default.
- W4288926425 cites W2139836848 @default.
- W4288926425 cites W2147246240 @default.
- W4288926425 cites W2147757009 @default.
- W4288926425 cites W2150587745 @default.
- W4288926425 cites W2153558008 @default.
- W4288926425 cites W2165885469 @default.
- W4288926425 cites W2171356556 @default.
- W4288926425 cites W2310716991 @default.
- W4288926425 cites W2404692795 @default.
- W4288926425 cites W2605767476 @default.
- W4288926425 cites W2724409437 @default.
- W4288926425 cites W2742627598 @default.
- W4288926425 cites W2744261860 @default.
- W4288926425 cites W2751075585 @default.
- W4288926425 cites W2771658548 @default.
- W4288926425 cites W2792232222 @default.
- W4288926425 cites W2797584152 @default.
- W4288926425 cites W2801641802 @default.
- W4288926425 cites W2801763724 @default.
- W4288926425 cites W2802559042 @default.
- W4288926425 cites W2810308581 @default.
- W4288926425 cites W2903062212 @default.
- W4288926425 cites W2903225254 @default.
- W4288926425 cites W2909854490 @default.
- W4288926425 cites W2914763076 @default.
- W4288926425 cites W2923453543 @default.
- W4288926425 cites W2927138762 @default.
- W4288926425 cites W2928384177 @default.
- W4288926425 cites W2983366686 @default.
- W4288926425 cites W2984927918 @default.
- W4288926425 cites W2990867581 @default.
- W4288926425 cites W3006331283 @default.
- W4288926425 cites W3024978145 @default.
- W4288926425 cites W3032554263 @default.
- W4288926425 cites W3033904414 @default.
- W4288926425 cites W3034162969 @default.
- W4288926425 cites W3043369050 @default.
- W4288926425 cites W3082855561 @default.
- W4288926425 cites W3087179831 @default.
- W4288926425 cites W3088753895 @default.
- W4288926425 cites W3094642003 @default.
- W4288926425 cites W3095855647 @default.
- W4288926425 cites W3096470811 @default.
- W4288926425 cites W3096548119 @default.
- W4288926425 cites W3101826014 @default.
- W4288926425 cites W3104690726 @default.
- W4288926425 cites W3119227305 @default.
- W4288926425 cites W3128028170 @default.
- W4288926425 cites W3132205831 @default.
- W4288926425 cites W3134918815 @default.
- W4288926425 cites W3137447968 @default.
- W4288926425 cites W3160154881 @default.
- W4288926425 cites W3161133732 @default.
- W4288926425 cites W3167870450 @default.
- W4288926425 cites W3174891250 @default.
- W4288926425 cites W3176807750 @default.
- W4288926425 cites W3198713553 @default.
- W4288926425 cites W3209622492 @default.
- W4288926425 cites W3211722088 @default.
- W4288926425 cites W3213050308 @default.
- W4288926425 cites W3213879987 @default.
- W4288926425 cites W4200014243 @default.
- W4288926425 cites W4200100973 @default.
- W4288926425 cites W4200201081 @default.
- W4288926425 cites W4200303223 @default.
- W4288926425 cites W4200488914 @default.
- W4288926425 cites W4213103558 @default.
- W4288926425 cites W4221044986 @default.
- W4288926425 cites W4221125141 @default.
- W4288926425 cites W4281660994 @default.
- W4288926425 cites W4281720947 @default.
- W4288926425 cites W4281724102 @default.
- W4288926425 cites W4281732590 @default.
- W4288926425 cites W4283023614 @default.
- W4288926425 doi "https://doi.org/10.1016/j.ctrv.2022.102443" @default.
- W4288926425 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35933930" @default.